Johnson & Johnson raised U.S. prices on around two dozen drugs, including psoriasis treatment, Stelara, prostate cancer drug, Zytiga, and blood thinner, Xarelto.
Related Biotechnology, Pharmaceutical and Healthcare News
Biotechnology Business Alliances
Astrazeneca
Bioethics
Boehringer
Clinical Research Organization
Collaborations
GSK
Johnson & Johnson
Lilly
Merck
Mergers and Acquisitions
Nexium
Novartis
Pfizer
Roche
Sanofi
...
Psoriasis Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...